Acquiring Company
AbbVie Inc.
Acquired Company
Cerevel Therapeutics
North ChicagoCambridgeManufacturingBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharmaPharmaceutical ManufacturingDescription
AbbVie has announced its plan to acquire Cerevel Therapeutics in a cash deal valued at approximately $8.7 billion. This acquisition aims to bolster AbbVie's pipeline in psychiatric and neurological disorders. The agreement is subject to regulatory approvals and customary closing conditions, following a favorable shareholder vote.
Fundz sees it the moment AbbVie Inc. makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Cerevel Therapeutics?
Cerevel Therapeutics was acquired by AbbVie Inc., based in North Chicago. The deal was reported on May 16, 2026. Venture capital subsidiary of Abbvie AbbVie Inc. is publicly traded (ABBV) and operates in Manufacturing.
When did AbbVie Inc. acquire Cerevel Therapeutics?
AbbVie Inc.'s acquisition of Cerevel Therapeutics was reported on May 16, 2026. AbbVie has announced its plan to acquire Cerevel Therapeutics in a cash deal valued at approximately $8.7 billion. This acquisition aims to bolster AbbVie's pipeline in psychiatric and neurological disorders. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Cerevel Therapeutics do?
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. It is privately held, operating in Pharmaceutical Manufacturing, and is based in Cambridge.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.